• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Peripheral artery disease Companies

    ID: MRFR/MED/1011-CR
    137 Pages
    Kinjoll Dey
    February 2020

    Peripheral Artery Disease (PAD) is a condition characterized by the narrowing or blockage of arteries that supply blood to the limbs, typically the legs. Companies involved in the management and treatment of Peripheral Artery Disease often offer medical devices, medications, and interventional therapies to address the symptoms and complications associated with this condition.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Peripheral Artery Disease Market Research Report - Forecast till 2032 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Peripheral artery disease Market

    Peripheral Artery Disease CompaniesLatest Peripheral Artery Disease Companies Update



    • Oct 2023: The benefits of a comeback in elective treatments should be evident in Boston Scientific's quarterly results, allaying concerns that the medical equipment manufacturer would suffer from the rising popularity of weight-loss medications. Concerns that well-liked new GLP-1 medications, such as Novo Nordisk's Ozempic and Wegovy, which are licensed to treat diabetes and weight reduction, may eat into the market for devices used by diabetic patients as well as bariatric surgery, have caused shares in the entire industry to plummet in recent months. Due to its very minor bariatric exposure, analysts have stated that Boston Scientific is unlikely to encounter any pressure from GLP-1s in the third quarter or soon and that it is uncertain how this may affect the company's heart devices in the long run.




    • Feb 2023: The market leader in medical radar monitoring and imaging technology (ReDSTM), Sensible Medical Innovations, and Terumo India, the Indian division of Terumo Corporation, an international innovator in medical technology, announced their partnership, which gives Terumo India exclusive distribution rights for ReDS ProTM and knowledge-sharing of ReDSTM technology in India. Patients' absolute lung fluid volume is measured with ReDSTM Pro, and there is a substantial link between this measurement and the symptoms of congestive heart failure (CHF). Measuring using this non-invasive procedure takes forty-five seconds. ReDSTM Pro lung fluid assessment is just as accurate as CT scan measurements. ReDSTM Pro monitoring regularly and medication adjustment in heart failure patients may cut hospitalization rates by up to 30%. ReDSTM technology, originally developed for the Israeli military to see through barriers, has been repurposed for use in medicine.


    List of Peripheral Artery Disease Key companies in the market

    • Philips N.V.,

    • Braun Melsungen AG,

    • Medtronic,

    • Bayer AG,

    • Boston Scientific Corporation,

    • Becton Dickinson and Company,

    • Terumo Medical Corporation,

    • Biotronik

    • Cardinal Health